Hinge Bio

Private

Burlingame, CaliforniaHealthcare & Life Scienceshttps://hingebio.com/

Last Round

Series A

Jan 15, 2025

Est. Valuation

$46M

Total Funding Raised

$30M

Company Overview

Hinge Bio is a biotechnology company that develops multispecific antibody therapeutics for autoimmune diseases, inflammatory diseases, and cancer using its proprietary GEM-DIMER™ platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

multispecific antibodybiotechnologydrug discoveryantibody therapeuticsbiotechclinical-stage biotechantibody engineeringB cell-mediated diseasesdrug developmentlicensing agreementpharma partneringtherapeutic pipelinedrug pipelinepreclinical researchclinical trials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hinge Bio Comps

Public and private peers based on sector, stage, and business model.

Hinge Bio comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Hinge Bio Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Jan 15, 2025

View all Funding Rounds

Key People

Founding team and executive leadership

Carin Rollins

Co-Founder COO

Founding Team

Barry Selick

Chief Executive Officer

Executive Team

Hinge Bio Investors

Notable investors and investment history

Hinge Bio investors
Investor	Rounds
Thornapple River Capital	Series A
Ridgeback Capital	Series A
InVivium Capital	Series A
Point72	Series A
Lightswitch Capital	Series A
Point72 Ventures	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Oct 13, 2025
Regulatory milestone achieved for Lupus therapy, enabling clinical trials.
Oct 1, 2025
Partnered with Kyorin Pharmaceutical Co., Ltd. for multispecific antibody medicines.

View all signals

Hinge Bio Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Hinge Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hinge Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlingame, California

Employee Range20

Year Founded2015

Last FundingJan 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.